Mobile

Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-002351-15

Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this trial is to demonstrate the effect of ONO 4641 versus interferon (IFN) ? 1a (Avonex) 30 µg on the proportion of subjects, with relapsing-remitting multiple sclerosis (RRMS), who remain qualifying relapse?free during their participation in the trial when the last evaluable subject completes 1 year. El objetivo principal de este ensayo es demostrar el efecto de ONO-4641 en comparación con interferón (IFN)-?-1a (Avonex) 30 µg sobre la proporción de pacientes con esclerosis múltiple recurrente remitente (EMRR), que continúen sin presentar recaídas aptas durante su participación en el ensayo cuando el último paciente evaluable complete 1 año

Critère d'inclusion

  • Relapsing-Remitting Multiple Sclerosis,Esclerosis Múltiple Remitente-Recidivante

Liens